Uploaded September 2025 | Updated September 2026, 15 hours ago
How do cancer cells resist therapies designed to stop them? This video explores breakthrough research from the Taylor Lab on Bruton’s tyrosine kinase (BTK) mutations and their role in chronic lymphocytic leukemia (CLL).
Learn how innovative BTK degraders like NX-2127 are changing the landscape of treatment.
In this explainer video, we show how BTK inhibitor therapies, widely used to treat CLL, face challenges when resistance mutations emerge. These mutations fall into two categories: kinase proficient and kinase impaired. Even without normal kinase activity, CLL cells can survive by using BTK as a scaffold to maintain B cell receptor signaling.
This discovery led to the development of heterobifunctional molecules that degrade BTK directly. NX-2127, the first-in-class BTK degrader, has already shown greater than 80 percent BTK degradation in CLL patients during clinical trials.
Led by Dr. Justin Taylor at the University of Miami Sylvester Comprehensive Cancer Center, this research represents a major step forward in understanding resistance and developing new therapies. Results were published in Science in 2024.
Learn more: justintaylorlab.com
#TaylorLab #CLL #LeukemiaResearch #BTK #CancerTherapy #ExplainerVideo #NX2127 #CancerInnovation
How do cancer cells resist therapies designed to stop them? This video explores breakthrough research from the Taylor Lab on Bruton’s tyrosine kinase (BTK) mutations and their role in chronic lymphocytic leukemia (CLL).
Learn how innovative BTK degraders like NX-2127 are changing the landscape of treatment.
In this explainer video, we show how BTK inhibitor therapies, widely used to treat CLL, face challenges when resistance mutations emerge. These mutations fall into two categories: kinase proficient and kinase impaired. Even without normal kinase activity, CLL cells can survive by using BTK as a scaffold to maintain B cell receptor signaling.
This discovery led to the development of heterobifunctional molecules that degrade BTK directly. NX-2127, the first-in-class BTK degrader, has already shown greater than 80 percent BTK degradation in CLL patients during clinical trials.
Led by Dr. Justin Taylor at the University of Miami Sylvester Comprehensive Cancer Center, this research represents a major step forward in understanding resistance and developing new therapies. Results were published in Science in 2024.
Learn more: justintaylorlab.com
#TaylorLab #CLL #LeukemiaResearch #BTK #CancerTherapy #ExplainerVideo #NX2127 #CancerInnovation
